CliffBio
small molecule

BREXPIPRAZOLE

BREXPIPRAZOLE

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameBREXPIPRAZOLE
Active ingredientBREXPIPRAZOLE
Strength0.25MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2025
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.